80
Views
1
CrossRef citations to date
0
Altmetric
Anticancer Original Research Paper

LncRNA DLEU2 contributes to Taxol resistance of gastric cancer cells through regulating the miR-30c-5p-LDHA axis

, &
Pages 49-60 | Received 14 Jul 2022, Accepted 11 Apr 2023, Published online: 09 May 2023

References

  • Smyth EC, Nilsson M, Grabsch HI, et al. Gastric cancer. Lancet. 2020;396(10251):635–648.
  • Tan Z. Recent advances in the surgical treatment of advanced gastric cancer: a review. Med Sci Monit. 2019;25:3537–3541.
  • Johnston FM, Beckman M. Updates on management of gastric cancer. Curr Oncol Rep. 2019;21(8):67.
  • Machlowska J, Baj J, Sitarz M, et al. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. IJMS. 2020;21(11):4012.
  • Alipour M. Molecular mechanism of Helicobacter pylori-Induced gastric cancer. J Gastrointest Cancer. 2021;52(1):23–30.
  • Gallego-Jara J, Lozano-Terol G, Sola-Martínez RA, et al. A compressive review about Taxol®: history and future challenges. Molecules. 2020;25(24):5986.
  • Galletti E, Magnani M, Renzulli ML, et al. Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem. 2007;2(7):920–942.
  • Yu DL, Lou ZP, Ma FY, et al. The interactions of paclitaxel with tumour microenvironment. Int Immunopharmacol. 2022;105:108555.
  • Wu G, Qin XQ, Guo JJ, et al. AKT/ERK activation is associated with gastric cancer cell resistance to paclitaxel. Int J Clin Exp Pathol. 2014;7(4):1449–1458.
  • Wei L, Sun J, Zhang N, et al. Noncoding RNAs in gastric cancer: implications for drug resistance. Mol Cancer. 2020;19(1):62.
  • Xu J, Xu Y, Ye G, et al. LncRNA-SNHG1 promotes paclitaxel resistance of gastric cancer cells through modulating the miR-216b-5p-hexokianse 2 axis. J Chemother. 2022;22(12):1–12.
  • Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and function. J Cell Biol. 2021;220(2):e202009045.
  • Ali Syeda Z, Langden SSS, Munkhzul C, et al. Regulatory mechanism of MicroRNA expression in cancer. IJMS. 2020;21(5):1723.
  • Mirzaei S, Paskeh MDA, Okina E, et al. Molecular landscape of LncRNAs in prostate cancer: a focus on pathways and therapeutic targets for intervention. J Exp Clin Cancer Res. 2022;41(1):214.
  • Hill M, Tran N. miRNA interplay: mechanisms and consequences in cancer. Dis Model Mech. 2021;14(4):dmm047662.
  • Venkatesh J, Wasson MD, Brown JM, et al. LncRNA-miRNA axes in breast cancer: novel points of interaction for strategic attack. Cancer Lett. 2021;509:81–88.
  • Cao JM, Li GZ, Han M, et al. MiR-30c-5p suppresses migration, invasion and epithelial to mesenchymal transition of gastric cancer via targeting MTA1. Biomed Pharmacother. 2017;93:554–560.
  • Herichova I, Reis R, Hasakova K, et al. Downregulation of miR-30c-5p expression in colorectal cancer tissue is sex-dependent. Physiol Res. 2020;69(Suppl. 3):S479–S487.
  • Zhou Y, Shi H, Du Y, et al. lncRNA DLEU2 modulates cell proliferation and invasion of non-small cell lung cancer by regulating miR-30c-5p/SOX9 axis. Aging (Albany NY). 2019;11(18):7386–7401.
  • Vaupel P, Schmidberger H, Mayer A. The warburg effect: essential part of metabolic reprogramming and Central contributor to cancer progression. Int J Radiat Biol. 2019;95(7):912–919.
  • Vaupel P, Multhoff G. Revisiting the warburg effect: historical dogma versus current understanding. J Physiol. 2021;599(6):1745–1757.
  • Icard P, Shulman S, Farhat D, et al. How the warburg effect supports aggressiveness and drug resistance of cancer cells? Drug Resist Updat. 2018;38:1–11.
  • Han S, Qi Y, Xu Y, et al. lncRNA DLEU2 promotes gastric cancer progression through ETS2 via targeting miR-30a-5p. Cancer Cell Int. 2021;21(1):376.
  • Karagkouni D, Karavangeli A, Paraskevopoulou MD, et al. Characterizing miRNA-lncRNA interplay. Methods Mol Biol. 2021;2372:243–262.
  • Feng Y, Xiong Y, Qiao T, et al. Lactate dehydrogenase A: a key player in carcinogenesis and potential target in cancer therapy. Cancer Med. 2018;7(12):6124–6136.
  • Zhang H, Wang X, Zhang Q, et al. DLEU2 participates in lymphovascular invasion and inhibits cervical cancer cell proliferation, migration, and invasion. Int J Clin Exp Pathol. 2020;13(8):2018–2026.
  • He M, Wang Y, Cai J, et al. LncRNA DLEU2 promotes cervical cancer cell proliferation by regulating cell cycle and NOTCH pathway. Exp Cell Res. 2021;402(1):112551.
  • Yang J, Huang Y, Dong B, et al. Long noncoding RNA DLEU2 drives the malignant behaviors of thyroid cancer through mediating the miR-205-5p/TNFAIP8 axis. Endocr Connect. 2021;10(4):471–483.
  • Xu B, Gong X, Zi L, et al. Silencing of DLEU2 suppresses pancreatic cancer cell proliferation and invasion by upregulating microRNA-455. Cancer Sci. 2019;110(5):1676–1685.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.